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Defined Daily Doses (DDD) and Defined Course Doses (DCD) have been established
in both human and veterinary medicine in order to standardize the measurement of
treatments in a population. In 2016 the European Medicines Agency published average
defined daily dose (DDDvet) and defined course dose (DCDvet) values for antimicrobial
agents used in livestock production. Similarly, national defined doses (DDDch and
DCDch) for the pig sector in Switzerland have recently been determined. The aim of
this study was to compare the outcome of calculating antimicrobial consumption based
on either DDDvet/DCDvet or DDDch/DCDch. Data from 227 Swiss pig farms describing
antimicrobial use in 2015 was collected. The numbers of treatment days and treatments
were calculated using DDDvet/DCDvet and DDDch/DCDch respectively, for each farm in
total and for different antimicrobial classes. Associations between calculated numbers
of DDDvet/DCDvet and DDDch/DCDch on farm level were investigated. In addition,
differences concerning antimicrobial use were investigated between different production
types of farms (piglet-producer, finishing farm or farrow-to-finishing farm). Using
DDDch/DCDch values we calculated 1,805,494 treatment days and 433,678 treatments
compared to 1,456,771 treatment days (19% ratio) and 303,913 treatments (30%
ratio) based on DDDvet/DCDvet. Penicillins (21.4/26.6%), polypeptides (18.6/27.6%)
and fluoroquinolones (9.5/8.8%) were the most frequently used classes of antimicrobials
based on calculation using both DDDch and DDDvet. Similar findings were observed
for complete treatments (DCDch/vet) (penicillins: 52.8/39.6%; polypeptides: 7.8/14.2%;
fluoroquinolones: 13.2/12.9%). The number of treatment days or treatments per farm
was higher for piglet-producers and farrow-to-finishing farms compared to finisher
farms regardless of whether Swiss or European DDD or DCD values were used for
the calculation (each P < 0.001). Similar results for antimicrobial use (AMU) obtained
at farm level were observed when calculated either by Swiss or European definitions.
Nevertheless, marked differences could be observed in the assessment of the use
of specific antimicrobial classes in the field based on DDDvet/DCDvet compared
to DDDch/DCDch.
Keywords: antimicrobial drug usage, antimicrobial classes, defined daily dose, defined course dose, European
medicines agency, monitoring systems, pigs, Switzerland
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INTRODUCTION
Antimicrobial use (AMU) is associated with the selection of
resistant pathogens (1, 2) and the spread of resistance both within
and between human and veterinary medicine (3–5). Responsible
use of antimicrobials is therefore essential (6).
The importance of antimicrobial resistance for public health is
internationally acknowledged (7, 8) and AMU in food-producing
animals is monitored by various authorities (9, 10) in order to
determine trends in resistance development.
In addition to monitoring systems measuring the amount
of active ingredients, systems based on application equivalents
have been established in several countries to monitor AMU in
veterinary medicine (11–13). These application equivalents,
originally developed for humans (14), standardize the
measurement of AMU (15), by taking into account the
dosages of the various antimicrobial compounds, and defining
a dosage required daily or for a whole treatment. In line with
the formal definition of the World Health Organization (WHO),
Defined Daily Doses (DDD) and Defined Course Doses (DCD)
are the assumed average maintenance doses per day or total
treatment duration (16), which allow the estimation of number
of treatment days respectively, number of treatments in a
population (17).
In 2016, following these principles, the European Medicines
Agency (EMA) published average defined daily dose (DDDvet)
and defined course dose (DCDvet) values for antimicrobial
agents used in livestock production as a tool to facilitate
standardized collection and presentation of AMU among
European member states (18). These values were defined
by calculating the mean of given registrations for livestock
production from nine different European countries. In analogy
with the principles of the EMA (19), national defined doses
(DDDch and DCDch) for each individual registration in the
pig sector in Switzerland were recently determined and some
theoretically discrepancies between Swiss and European values
have been described in a prior study (20).
The aim of this study was to investigate the outcome of
calculated antimicrobial consumption in the field based on
either individual, Swiss values (DDDch/DCDch) or average,
European values (DDDvet/DCDvet). The impact of using
either DDD/DCDch or DDD/DCDvet values were tested for
different age groups, administration routes and antimicrobial
classes. Moreover, the impact of using either DDD/DCDch or
DDD/DCDvet for evaluation of antimicrobial use on the study
Number of Defined Doses =
total amount of prescribed antimicrobial ingredient (mg)
DDDvet or DDDch or DCDvet or DCDch
(
mg
kg
)
× standard weight of age group (kg)
farms was considered, as well as differences in antimicrobial
usage by farm type.
The questions behind all these investigations were: Will an
AMU monitoring system based on either Swiss or European
definitions lead to comparable results in the field or not? And
for which age groups, administration routes and antimicrobial
classes can the most frequent AMU be observed in the pig sector
of Switzerland?
MATERIALS AND METHODS
Data Collection
In cooperation with the Swiss Swine Health Service (SSHS),
data from 227 Swiss pig farms concerning antimicrobial use in
2015 was collected, thus representing 3.3% of all pig farms in
Switzerland in 2015 (21). All 227 farms joined a nationwide
voluntary program for pig producers in Switzerland in order
to evaluate and improve transparency of AMU on their farms.
Only farms with a complete documentation of antimicrobial
ingredients purchased in the year 2015 were included in the
study. The study farms were required to provide documentation
of all veterinary prescriptions of antimicrobials for this year,
including exact information about the name and the amount
of the used products. Farmers were required to allocate the
prescribed antimicrobials to four different groups (sow, finisher
pig, weaner, and piglet). The documentation had to be reported
once every 3 months during the year. In addition to AMU
records, numbers of pigs kept (sows) or produced annually (all
other age groups) and the type of farm were also documented.
Overall 96 piglet-producing farms, 42 farrow-to-finish pig farms
and 89 finishing farms housing a total of 328,909 piglets, 292,298
weaners, 179,144 finishing pigs and 11,710 sows were included
in the study. The number of sows were representing 9.5% of
all sows kept in Switzerland, which were notified in 2015 (21).
The mean farm size was 85 sows with 2,383 produced piglets
and 2,108 produced weaners in the year 2015, including the data
of all piglet-producing and farrow-to-finish farms. The mean of
the produced finishing pigs was 1,303, combined the data of the
farrow-finish farms and the finishing farm, respectively. A piglet-
producing farm housing at least 30% piglets from birth until time
of slaughter was considered as farrow-to-finish farm.
AMU Quantification
In order to quantify AMU, the amount of prescribed
antimicrobial ingredient during the year 2015 of all participating
farms was divided by the defined doses (DDD/DCDvet or
DDD/DCDch) of the corresponding antimicrobial classes
multiplied by the standard weights of the different age
groups as defined by the European Surveillance of Veterinary
Antimicrobial Consumption (ESVAC) (piglets: 4 kg; weaners:
12 kg; finisher pig: 50 kg and sow: 220 kg) (22).
The recently published, national defined daily and course
doses for the pig sector in Switzerland were drawn up in
accordance with the principles of the EMA (19). In order
to establish DDDch and DCDch, the required information
on dosage and treatment duration was generally taken
from the product approvals which are summarized in the
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Swiss Veterinary Medicines Compendium (23). The detailed
procedure of defining the national doses and all values for
DDDch and DCDch is accessible as Supplementary Data.
A product and the farm using it were excluded from
the study when corresponding DDD/DCDvet values had
not been published by the EMA either for the specific
antimicrobial ingredient or a comparable antimicrobial
ingredient, a given combination of substances or a specific
administration route.
The number of defined doses and the amount of prescribed
antimicrobial ingredient were calculated in total, for the different
age groups, different administration routes (injection, oral, and
premix) and for all antimicrobial classes. The term premix
included all antimicrobial ingredients to be administered via the
feed and/or water. By dividing the results using DDD/DCDvet by
those based on DDD/DCDch, differences of Swiss or European
definitions were investigated for the calculated AMU. The
results of this calculations were termed ratio. A positive ratio
with results > 0 indicated a higher number of estimated
treatment days or treatments could be observed when using
the European definitions DDD vet or DCDvet. In addition,
the overall observed mean treatment durations given by the
Swiss or European defined values were compared in the
same way.
For the evaluation of the AMU at the farm level and
in order to compare the consumption on different farms,
the number of kept (sows) or produced pigs (other age
groups) in the year 2015 were taken into account. The
amount of prescribed antimicrobial ingredients was divided
by the different defined doses, the standard weights and
the number of pigs for each age group. If necessary,
the results of the different age groups were summarized
together and the number of Defined Doses per farm
TABLE 2 | Total antimicrobial use (AMU) measured as active ingredient and by
Swiss and European defined dosage grouped by different antimicrobial classes.
Antimicrobial
classes
Amount of active
ingredient in kg
DDDcha DDDvetb DCDchc DCDvetd
Aminoglycosides 25.7 67,273 59,973 20,918 15,255
Amphenicols 0.03 44 69 22 22
Cephalosporins 0.3 2,200 2,299 733 636
Fluoroquinolones 6.0 171,518 127,880 57,173 39,064
Lincosamides 0.7 26,217 20,456 2,777 2,997
Macrolides 21.4 293,108 120,006 33,286 15,148
Penicillins 77.8 385,507 388,221 229,006 120,394
Pleuromutilins 4.0 14,388 11,289 1,188 1,623
Polypeptides 26.0 335,498 402,708 33,687 43,006
Pyrimidines 2.1 6,613 6,252 1,653 1,705
Sulfonamides 144.1 228,817 98,192 23,946 30,848
Tetracyclins 113.1 274,311 219,426 29,289 33,215
aDDDch: Number of treatment days based on Swiss Defined Daily Doses.
bDDDvet: Number of treatment days based on Defined Daily Doses of the European
Medicine Agency (EMA).
cDCDch: Number of treatments based on Swiss Defined Course Doses.
dDCDvet: Number of treatments based on Defined Course Doses of the European
Medicine Agency (EMA).
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was calculated.
Number of Defined Doses per farm =
total amount of prescribed antimicrobial ingredient per farm and age group (mg)
DDDvet or DDDch or DCDvet or DCDch
(
mg
kg
)
× standard weight of age group (kg)× number of pigs per farm and age group
Data Processing and Statistical Analysis
The preparation of all operating farm data and the calculation
of the number of defined doses was carried out using
Microsoft Excel 2011 (Microsoft, Redmond, WA, USA). The
statistical analysis and preparation of graphs to visualize
the results was performed with R (https://cran.r-project.org).
Differences between the tested groups having a P ≤ 0.05
were considered statistically significant. The data for calculated
AMU on farm level was tested for normality by the Shapiro-
Wilk test. The association of Swiss and European dosages
for a possible AMU monitoring system on the farms was
evaluated using scatterplots and correlation analysis performed
by Spearman’s rho test. The differences between the various
farm structures were investigated using the Kruskal-Wallis
test for independent samples and post hoc pairwise analysis
(Bonferroni correction).
RESULTS
AMU Quantification per Age Group and
Administration Route
In this study, the AMU was calculated at 1,805,494 DDDch
and 433,678 DCDch when based on Swiss values, compared to
1,456,771 DDDvet (−19.3% ratio) and 303,913 DCDvet (−29.9%
ratio) based on European defined doses (Table 1). The mean
treatment duration was 3.7 days based on Swiss values and 4.0
days based on European values. The largest fraction of DDD was
calculated for weaners, regardless of Swiss DDDch (64.4%) or
European DDDvet (60.3%), whereas for DCDs based on Swiss
definitions, piglets represented the major part of the treatments
(53.1%). Based on European definitions most calculated course
doses were observed for weaners (44.8%). Ratios of more than
20% between the calculated numbers of DDD/DCDch and
FIGURE 1 | Relative distribution of antimicrobial use (AMU) between different antimicrobial classes measured either as the amount of active ingredient or as the
number of defined daily doses (DDD) or defined course doses (DCD), respectively. DDD and DCD were calculated with Swiss values (DDDch and DCDch) or European
values (DDDvet or DCDvet) published by the European Medicine Agency (EMA). (Amphenicols and cephalosporins as well as lincosamides are not inscribed due to
the low values).
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DDD/DCDvet, respectively could be observed for the number
of DDDch/vet of weaners and finisher pigs and for DCDch/vet
of piglets, finisher pigs, and sows. The largest quantity of
active ingredients was given to the groups of weaners (49.4%),
followed by finisher pigs (32.7%), sows (14.2%), and piglets
(3.6%). When investigating the different administration routes
by the number of defined doses, premixes represented the largest
proportion calculated by DDDch/vet (64.9/59.5%) in contrast to
injectable products when calculating the number of DCDch/vet
(71.3/60.2%). Relative differences of more than ±20% could be
observed for oral and premix treatments when calculated in
DDDch and DDDvet, respectively, and for oral and parenteral
treatments when calculated in DCDch or DCDvet. The treatment
duration was longer when the calculation was based on
DDD/DCDvet compared to DDD/DCDch, except for treatments
of weaners in general and for treatments with premixes.
AMU Quantification per Antimicrobial
Classes
The amount of active ingredient and the calculated numbers
of defined doses for different antimicrobial classes were
summarized in Table 2 and the relative distribution was
visualized in Figure 1. Considering the amount of active
ingredient used, the classes of sulfonamides (144,086,000
mg/34.3%), tetracyclines (113,122,600 mg/26.9%), and
penicillins (77,788,850 mg/18.5%) represented the largest
proportion of the total usage, whereas when using defined
daily doses, penicillins (DDDch: 385,507/21.4%; DDDvet:
388,221/26.6%) and polypeptides (DDDch: 335,498/18.6%;
DDDvet: 402,708/27.6%) were the most frequent. Macrolides
were observed to represent 16.2% of the total usage (293,108
treatment days) calculated in DDDch. Penicillins (DCDch:
229,006/52.8%; DCDvet: 120,394/39.6%) and fluroquinolones
(DCDch: 57,173/13.2%; DCDvet: 39,064/12.9%) were common
for the number of total treatments, as well as polypeptides
(DCDvet: 43,006/14.2%) for calculations based on the European
values. The percentage of fluoroquinolones in total AMU was
1.4% when considering the amount in mg, compared to 8.8 and
13.2% when calculating DDDvet and DCDch, respectively.
A more detailed, combined consideration of age groups,
administration routes, and antimicrobial class data shows that
injection was the most frequent administration route for piglets
independent of the method used for calculation, and that
within this group penicillins and fluoroquinolones were the
most frequently used antimicrobials (Table 3). The use of
premixes was the most frequently used administration route for
weaners independent of the indicator used and polypeptides
were most frequently used when considering the number of
defined daily doses. For the number of calculated doses based
on DDD/DCDch, frequent use of macrolides was notable
in the premixes given to weaners whereas sulfonamides and
tetracyclines were more frequently used when the calculation
was based on DDD/DCDvet. In terms of the finisher pig group,
injection and premixes were observed with similar frequencies
for administration routes, when either daily doses or course
doses were the basis of the calculation. Oral administration of
premixes was the most common administration route when
calculating AMU based on defined doses. Contrastingly, when
calculating in course doses, injections represented the largest
proportion of treatments. Penicillins and aminoglycosides were
frequently used injections for finisher pigs and tetracyclines were
the most commonly used antimicrobial class given as premix. As
was the case in weaners, macrolides represented a considerable
proportion of treatments based on DDDch as well as DCDch. In
sows, most antimicrobials were given by injections and within
this group, most of the antimicrobials administered belonged
to the antimicrobial classes of penicillins and fluoroquinolones.
The most frequently administered antimicrobial class provided
as a premix was the class of penicillins. An administration of
oral antimicrobials without feed or water was only observed for
fluoroquinolones and polypeptides in piglets and on only two
farms with a small amount in weaners.
AMU Monitoring on Farm Level
Each dataset was tested for normality by Shapiro-Wilk test and
for all datasets, independent of Swiss or European measuring
method or type of farm, the null hypothesis was rejected (each
P < 0.001).
The scatterplot of calculated defined daily doses (DDD) and
defined course doses (DCD), analyzing the association between
Swiss (ch) and European (vet) definitions, is given in Figure 2.
As shown, both the calculated number of daily doses and the
calculated number of course doses showed a positive correlation
between results on the farm level by Spearman’s rho test.
Consideration of structure of the various farms pointed to
a higher amount of calculated AMU per farm and per year on
farrow-to-finishing farms and piglet-producing farms compared
to finishing farms for all Swiss or European values of defined
doses (P < 0.001) by Kruskal-Wallis-test and subsequent post
hoc pairwise analysis (Table 4, Figure 3). In terms of calculated
DDDch-numbers the median values were 4.40, 4.88, and 0.27
for farrow-to-finishing, piglet-producing and finishing farms,
respectively. No significant difference between the farrow-to-
finishing farms and the piglet-producers was observed for any of
the used values.
DISCUSSION
This study shows that although evaluating AMU for the pig sector
at the farm level based either on Swiss or European defined doses
leads to similar results with a positive correlated association,
there were still deviations in detail, i.e., in the assessment of the
different active substance classes, different administration routes
and various age groups. A possible on farm AMU monitoring
system will arrive at similar conclusions and farms with low or
high AMU consumption will be similarly assessed using both
methods. Since the Swiss definitions are based on individual
national approvals in comparison to the average EMA definitions
collected from nine countries, the Swiss definitions seem more
robust for a national evaluation of active substance classes,
administration routes and age groups.
The challenge of collecting adequate information on AMU in
the field is well-known and described in the literature (15). Since
Frontiers in Veterinary Science | www.frontiersin.org 5 July 2019 | Volume 6 | Article 240
E
c
h
te
rm
a
n
n
e
t
a
l.
A
M
U
o
n
S
w
iss
P
ig
F
a
rm
s
TABLE 3 | Distribution of antimicrobial use (AMU) per different age categories, administration routes and antimicrobial classes measured as active ingredient and by Swiss and European defined dosage.
Age group Administration
route
Antimicrobial
classes
Amount of active
ingredient in mg
DDDcha (n) (%) DDDvetb (n) (%) DCDchc (n) (%) DDDvetd (n) (%)
Piglets 15,117,075 473,922 428,546 230,237 132,433
Oral 118,250 0.8% 13,833 2.9% 10,065 2.3% 4,428 1.9% 2,428 1.8%
Fluoroquinolones 83,050 70.2% 12,458 90.1% 8,305 82.5% 4,153 93.8% 2,076 85.5%
Polypeptides 35,200 29.8% 1,375 9.9% 1,760 17.5% 275 6.2% 352 14.5%
Injection 14,764,825 97.7% 450,340 95.0% 406,781 94.9% 224,835 97.7% 128,760 97.2%
Aminoglycosides 2,662,850 18.0% 39,802 8.8% 36,445 9.0% 13,419 6.0% 9,661 7.5%
Cephalosporins 7,875 0.1% 880 0.2% 916 0.2% 293 0.1% 259 0.2%
Fluoroquinolones 1,281,725 8.7% 129,323 28.7% 95,830 23.6% 43,108 19.2% 29,632 23.0%
Lincosamides 297,500 2.0% 14,875 3.3% 9,535 2.3% 2,125 0.9% 2,010 1.6%
Macrolides 98,000 0.7% 2,450 0.5% 1,885 0.5% 817 0.4% 471 0.4%
Penicillins 10,118,275 68.5% 257,065 57.1% 253,251 62.3% 163,096 72.5% 83,993 65.2%
Pleuromutilins 20,000 0.1% 400 0.1% 417 0.1% 133 0.1% 227 0.2%
Pyrimidines 22,000 0.1% 1,857 0.4% 1,833 0.5% 464 0.2% 500 0.4%
Sulfonamides 110,000 0.7% 1,857 0.4% 1,782 0.4% 464 0.2% 480 0.4%
Tetracyclins 146,600 1.0% 1,833 0.4% 4,887 1.2% 916 0.4% 1,527 1.2%
Premix 234,000 1.5% 9,750 2.1% 11,700 2.7% 975 0.4% 1,245 0.9%
Polypeptides 234,000 100.0% 9,750 100.0% 11,700 100.0% 975 100.0% 1,245 100.0%
Weaners 207,658,150 1,143,175 878,525 151,483 136,136
Oral 450 0.0% 23 0.0% 15 0.0% 8 0.0% 4 0.0%
Fluoroquinolones 450 100.0% 23 100.0% 15 100.0% 8 100.0% 4 100.0%
Injection 8,654,000 4.2% 82,799 7.2% 89,073 10.1% 42,440 28.0% 28,684 21.1%
Aminoglycosides 755,300 8.7% 5,946 7.2% 4,621 5.2% 1,790 4.2% 1,252 4.4%
Cephalosporins 12,500 0.1% 486 0.6% 508 0.6% 162 0.4% 141 0.5%
Fluoroquinolones 567,400 6.6% 21,078 25.5% 16,860 18.9% 7,026 16.6% 5,237 18.3%
Lincosamides 62,500 0.7% 1,042 1.3% 668 0.7% 149 0.4% 141 0.5%
Macrolides 100,000 1.2% 833 1.0% 641 0.7% 278 0.7% 160 0.6%
Penicillins 5,955,400 68.8% 46,766 56.5% 52,806 59.3% 30,355 71.5% 17,753 61.9%
Pleuromutilins 10,000 0.1% 67 0.1% 69 0.1% 22 0.1% 38 0.1%
Pyrimidines 36,400 0.4% 1,264 1.5% 1,011 1.1% 316 0.7% 276 1.0%
Sulfonamides 182,000 2.1% 1,264 1.5% 1,083 1.2% 316 0.7% 310 1.1%
Tetracyclins 972,500 11.2% 4,052 4.9% 10,806 12.1% 2,026 4.8% 3,377 11.8%
Premix 199,003,700 95.8% 1,060,353 92.8% 789,437 89.9% 109,036 72.0% 107,448 78.9%
Aminoglycosides 268,400 0.1% 10,167 1.0% 6,578 0.8% 484 0.4% 828 0.8%
Lincosamides 268,400 0.1% 10,167 1.0% 10,167 1.3% 484 0.4% 828 0.8%
Macrolides 15,594,000 7.8% 264,722 25.0% 108,292 13.7% 29,222 26.8% 13,260 12.3%
Penicillins 5,613,500 2.8% 22,598 2.1% 27,517 3.5% 4,520 4.1% 2,613 2.4%
Pleuromutilins 400,000 0.2% 4,444 0.4% 3,436 0.4% 317 0.3% 412 0.4%
(Continued)
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TABLE 3 | Continued
Age group Administration
route
Antimicrobial
classes
Amount of active
ingredient in mg
DDDcha (n) (%) DDDvetb (n) (%) DCDchc (n) (%) DDDvetd (n) (%)
Polypeptides 22,934,400 11.5% 318,533 30.0% 382,240 48.4% 31,853 29.2% 40,664 37.8%
Sulfonamides 91,210,000 45.8% 200,556 18.9% 82,618 10.5% 20,056 18.4% 26,120 24.3%
Tetracyclins 62,715,000 31.5% 229,167 21.6% 168,589 21.4% 22,099 20.3% 22,723 21.1%
Finisher pigs 137,539,345 159,719 122,493 40,894 27,566
Injection 36,317,845 26.4% 59,832 37.5% 58,296 47.6% 31,176 76.2% 17,751 64.4%
Aminoglycosides 9,080,625 25.0% 8,386 14.0% 9,221 15.8% 3,872 12.4% 2,627 14.8%
Amphenicols 32,700 0.1% 44 0.1% 69 0.1% 22 0.1% 22 0.1%
Cephalosporins 31,500 0.1% 315 0.5% 332 0.6% 105 0.3% 89 0.5%
Fluoroquinolones 108,125 0.3% 915 1.5% 713 1.2% 305 1.0% 220 1.2%
Lincosamides 30,000 0.1% 120 0.2% 77 0.1% 17 0.1% 16 0.1%
Macrolides 653,600 1.8% 1,307 2.2% 1,006 1.7% 436 1.4% 251 1.4%
Penicillins 24,298,495 66.9% 46,202 77.2% 41,541 71.3% 25,360 81.3% 12,839 72.3%
Pleuromutilins 90,000 0.2% 144 0.2% 150 0.3% 48 0.2% 82 0.5%
Pyrimidines 58,000 0.2% 377 0.6% 387 0.7% 94 0.3% 105 0.6%
Sulfonamides 290,000 0.8% 377 0.6% 414 0.7% 94 0.3% 129 0.7%
Tetracyclins 1,644,800 4.5% 1,645 2.7% 4,386 7.5% 822 2.6% 1,371 7.7%
Premix 101,221,500 73.6% 99,887 62.5% 64,197 52.4% 9,718 23.8% 9,815 35.6%
Macrolides 4,897,000 4.8% 23,767 23.8% 8,162 12.7% 2,525 26.0% 999 10.2%
Penicillins 1,950,000 1.9% 1,917 1.9% 2,294 3.6% 383 3.9% 218 2.2%
Pleuromutilins 350,0000 3.5% 9,333 9.3% 7,216 11.2% 667 6.9% 864 8.8%
Polypeptides 1,752,000 1.7% 5,840 5.8% 7,008 10.9% 584 6.0% 746 7.6%
Sulfonamides 42,145,000 41.6% 21,567 21.6% 9,162 14.3% 2,210 22.7% 2,897 29.5%
Tetracyclins 46,977,500 46.4% 37,464 37.5% 30,355 47.3% 3,349 34.5% 4,091 41.7%
Sows 59,835,480 28,678 27,207 11,064 7,778
Injection 54,560,980 91.2% 27,489 95.9% 25,797 94.8% 10,826 97.8% 7,644 98.3%
Aminoglycosides 12,929,300 23.7% 2,972 10.8% 3,108 12.0% 1,352 12.5% 885 11.6%
Cephalosporins 236,525 0.4% 519 1.9% 544 2.1% 173 1.6% 148 1.9%
Fluoroquinolones 3,930,475 7.2% 7,722 28.1% 6,157 23.9% 2,574 23.8% 1,895 24.8%
Lincosamides 15,000 0.0% 14 0.0% 9 0.0% 2 0.0% 2 0.0%
Macrolides 62,000 0.1% 28 0.1% 22 0.1% 9 0.1% 5 0.1%
Penicillins 24,578,680 45.0% 9,769 35.5% 9,401 36.4% 5,054 46.7% 2,844 37.2%
Pyrimidines 1,993,800 3.7% 3,116 11.3% 3,021 11.7% 779 7.2% 824 10.8%
Sulfonamides 10,149,000 18.6% 3,197 11.6% 3,133 12.1% 806 7.4% 914 12.0%
Tetracyclins 666,200 1.2% 151 0.6% 404 1.6% 76 0.7% 126 1.7%
Premix 5,274,500 8.8% 1,189 4.1% 1,410 5.2% 238 2.2% 134 1.7%
Penicillins 5,274,500 100.0% 1,189 100.0% 1,410 100.0% 238 100.0% 134 100.0%
Numbers in bold are mentioned in the results part of the study.
aDDDch: Number of treatment days based on Swiss Defined Daily Doses.
bDDDvet: Number of treatment days based on Defined Daily Doses of the European Medicine Agency (EMA).
cDCDch: Number of treatments based on Swiss Defined Course Doses.
dDCDvet: Number of treatments based on Defined Course Doses of the European Medicine Agency (EMA).
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Echtermann et al. AMU on Swiss Pig Farms
FIGURE 2 | Scatterplots of defined daily doses (DDD) and defined course doses (DCD) at the farm level calculated either by Swiss values (DDDch/farm and
DCDch/farm). Each dataset was tested for normality by Shapiro-Wilk test and for all datasets the null hypothesis was rejected (each P < 0.001). So non-normal
distributed data was concluded and the correlation was investigated by Spearman’s rho test.
TABLE 4 | Median values of the defined daily doses (DDD) and defined course doses (DCD) based on the number of Switzerland (DDDch/farm and DCDch/farm) and the
European Medicine Agency (DDDvet/farm and DCDvet/farm) for the different type of farms (farrow-to-finish farm, finishing farm and piglet-producing farm).
DDDch/farm DDDvet/farm DCDch/farm DCDvet/farm
1) Farrow-to-finish farm 4.40 (0.67–16.02) 3.63 (0.83–15.46) 1.43 (0.27–4.48) 0.98 (0.239–3.63)
2) Finishing farm 0.27* (0–3.82) 0.26* (0–2.75) 0.08* (0–0.70) 0.077* (0–0.50)
3) Piglet-producing farm 4.88 (0.96–12.45) 3.99 (1.04–12.04) 1.22 (0.29–4.61) 1.05 (0.26–2.65)
10 and 90% percentiles are given in brackets. Each dataset was tested for normality by Shapiro-Wilk tests and for all datasets the null hypothesis was rejected (each P < 0.001). So
non-normal distributed data was concluded. By performing Kruskal-Wallis test for independent samples and post hoc pairwise analysis (Bonferroni correction) significant differences
between finishing farm and farrow-to-finish-farm respectively, piglet-producing farm could be observed (each P < 0.001). No significant differences between farrow-to-finishing farm
and piglet-producing farm could be observed (each P > 0.05). *P < 0.001 (to 1 and 3).
the participation in the present study and supply of data was
voluntary, some bias cannot be completely ruled out due to the
fact that knowledge and motivation of farmers have an influence
on AMU (24). We consider the coverage of the study population
to be adequate for our study goals with 3.3% of all Swiss pig farms
and 9.5% of all sows, and it allows to deduce that especially larger
farms seemed to be more motivated to participate in the study.
Since the data underlying this study did not include a record
about the length of pigs’ stay in the farrowing unit, the nursery
unit and the fattening unit, it is not feasible to make an exact
evaluation of how many theoretical treatment days or treatments
would be possible in the life span of a pig, as calculated by
Timmermann et al. (25). However, the calculation behind the
number of dosages on farm level is based on the population
of animals present or produced during 1 year and this makes
it comparable to other systems using defined doses to estimate
AMU per farm in livestock (11–13).
Since the present study is based on calculations from
prescribed amounts, the exact amounts of antimicrobials used
by the farmer cannot be assessed and overdosing as well as
underdosing could bias the results and the study only allows a
statistical estimation of the probable AMU.
Another aspect of this study which is shown in Table 1 is
the different evaluation of monitoring systems based either on
the measurement of the amount of active ingredient or on the
measurement of application equivalents such as defined doses:
due to the lower standard weight of piglets, a considerable
number of defined treatments can be performed with an amount
of antimicrobial suitable for a single treatment of just one sow. As
a consequence, the observed amount of active ingredients for e.g.,
piglets was low whereas the number of calculated doses was high.
This is in line with prior studies (26) and EMA advice cautioning
that differences in dosing between species and substances must
be taken into account when using DDD and DCD values (19).
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FIGURE 3 | Comparison of antimicrobial use in different types of farms (farrow-to-finish farms, finishing farms and piglet-producing farms) measured by the number of
defined daily doses (DDD) and defined course doses (DCD) per farm based on the values of Switzerland (DDDch/farm and DCDch/farm) and the European Medicine
Agency (DDDvet/farm and DCDvet/farm). Each dataset was tested for normality by Shapiro-Wilk test and for all datasets the null hypothesis was rejected (each
P < 0.001). So non-normal distributed data was concluded. By performing Kruskal-Wallis test for independent samples and post hoc pairwise analysis (Bonferroni
correction) significant differences between finishing farm and farrow-to-finish-farm respectively, piglet-producing farm could be observed (each P < 0.001).
No significant differences between farrow-to-finishing farm and piglet-producing farm could be observed (each P > 0.05).
In general, a low value for a defined dose results in a higher
number of calculated or estimated doses in a population (17).
This explains some differences between the number of DDDch
or DCDch on the one side and DDDvet and DCDvet on
the other side. For example, macrolides showed a difference
in calculated use depending on whether Swiss or European
definitions were chosen. As a previous study showed, there are
six Swiss premix products containing the macrolide tylosin with
much lower defined daily and course doses compared to the
values of the EMA (20), thus explaining the relatively high
number of DDDch and DCDch in this category. This general
understanding can also be used to explain the results in Table 1.
All groups with a high ratio between the calculation based on
Swiss or European definitions come by a frequent use with
approvals whose DDDch and DCDch values differ strongly from
the DDDvet and DCDvet values.
In accordance with a recently published study, the animal
groups with the highest numbers of treatment days and total
number of treatments observed were weaners (DDDch, DDDvet,
and DCDvet) and piglets (DCDch) (27). These groups are
most susceptible to bacterial infections and, at least for the
weaners, frequent group therapies at weaning can be assumed,
which is reflected in the high proportion of treatments with
premixes, as described by other studies (28). This assumption
is also underlined by the fact, that a longer Swiss treatment
duration could be observed only for weaned piglets and
for premixes and a relationship between both findings could
be hypothesized. Thus, young age groups should already be
considered in terms of resistance prevention and the use of group
therapies by premixes in feed in these groups should be critically
re-evaluated (29).
Furthermore, when calculating the number of DDDs,
relatively high use could be observed for premixes and in
contrast, a relatively high total number of course doses could
be observed for injections in this study. This can be explained
by the comparison of treatment durations between injections
and premixes, since the number of calculated course doses
decreases with the increase in treatment duration of the
premixes. Previous publications confirmed the high proportion
of premixes used in the pig sector in Switzerland (30, 31). An
increased risk of development of resistance for specific active
substances and bacteria is documented by this administration
route (32). Thus, group therapies should be reduced to the
necessary minimum.
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A relatively high proportion of treatments with Highest
Priority Critically Important Antimicrobials (HPCIAs) could be
observed in this study (e.g., 44.8% of DDDvet’s). These findings
are comparable to results recently published from the EFFORT
consortium (27), but varying from results of a previous study,
where a lower AMU quantification of HPCIAs for pigs in
Switzerland based on total amount of given active ingredient was
observed (33). Due to the documented spread of resistance genes
e.g., against fluoroquinolones in the pig sector (34), every use
of these substances should be of concern and further research
investigating restriction of indications and potential reductions
in usage is needed.
The results from the different farm types show again that the
younger age groups are most frequently treated. Both, farrow-
to-finishing farm as well as piglet-producing farms in contrast
to the finishing farms keep the high consumption age groups of
piglets and weaners. This could explain the significant difference.
Due to the small number of calculated defined doses of finisher
pigs, no significant difference between farrow-to-finishing and
piglet-producing farms was observed.
In order to gain a better understanding of the differences
between these individual farms, further studies are needed to
examine the role of the farmer (23) as well as AMU quantification
and performance data (35).
CONCLUSION
In summary, this study demonstrated a general association of
the AMU systems at the farm level, nevertheless, differences
were seen in detail according to whether the calculation
was based on individual Swiss or average European values.
The benefit of the European values for internationally
comparative AMU monitoring is undisputed, but for
a detailed evaluation, Swiss definitions could be more
accurate as they are based on the specific approvals of the
country. This must be considered in order to understand
international AMU comparisons in the future. The study
also highlighted the need to further evaluation for the
use of HPCIAs.
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